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The ETS domain transcription factor ELK1 is in a repressive
associationwith growth genes and is transiently activated through
phosphorylation by ERK1/2. In prostate cancer (PCa) cells the
androgen receptor (AR) is recruited by ELK1, via its amino-termi-
nal domain (A/B), as a transcriptional co-activator, without ELK1
hyper-phosphorylation. Here we elucidate the structural basis of
the interaction of AR with ELK1. The ELK1 polypeptide motifs
required for co-activation by AR versus those required for activa-
tion of ELK1byERKwere systematicallymappedusing amamma-
lian two-hybrid system and confirmed using a co-immunoprecipi-
tation assay. The mapping precisely identified the two ERK-
docking sites in ELK1, the D-box and the DEF (docking site for
ERK, FXFP) motif, as the essential motifs for its cooperation with
AR(A/B) or WTAR. In contrast, the transactivation domain in
ELK1 was only required for activation by ERK. ELK1-mediated
transcriptional activity of AR(A/B) was optimal in the absence of
ELK1 binding partners, ERK1/2 and serum-response factor. Puri-
fiedELK1andARboundwithadissociationconstantof1.9108
M. A purified mutant ELK1 in which the D-box and DEF motifs
were disrupted did not bindAR. An ELK1mutant with deletion of
theD-box region had a dominant-negative effect on androgen-de-
pendent growth of PCa cells that were insensitive to MEK inhibi-
tion. This novel mechanism in which a nuclear receptor impinges
ona signalingpathwayby co-optingproteinkinasedocking sites to
constitutivelyactivategrowthgenescouldenable rationaldesignof
a new class of targeted drug interventions.
The androgen receptor (AR)2 and other members of the
nuclear receptor (NR) superfamily mediate the transcriptional
activities of their ligands as well as some of their non-genomic
actions (1–5). NRs in the cytosol, in the nucleus, or in asso-
ciation with plasma membrane proteins are known to inter-
act with a variety of signaling pathway proteins, either as
protein kinase substrates or as regulators of transcription or
signal transduction. Although some of the client proteins of
NRs in these pathways have been identified, including those
shared by different NRs, there is a paucity of information on
the structural elements that enable the mutual recognition
of NRs and signaling proteins in both normal physiology and
in pathogenesis.
Most early stage and advanced prostate tumors depend on
AR for growth (6–11). The human AR is a 919-amino acid
polypeptide with a basic structural organization typical of NRs
(12). In the classical model of gene regulation by AR, ligand
binding is critical for several events, including release of AR
froma cytosolic chaperone complex aswell as phosphorylation,
stabilization, dimerization, and nuclear import of AR (12–14).
Ligand binding is also needed for optimal binding of AR to
DNA at well characterized response elements associated with
target genes (15, 16). However, advanced PCa cells may acquire
the ability to localize adequate AR to the nucleus where it is
transcriptionally active through mechanisms that include AR
amplification, hormone-independent phosphorylation of AR
through hyper-activated signaling pathways, or overexpression
of ligand-independent AR splice variants (17–20). Splice vari-
ants of AR have carboxyl-terminal truncations that lack the
ligand binding domain (21). The above cellular changes in
advanced PCa cells, as well as intratumoral androgen biosyn-
thesis, could render the tumors resistant to conventional
AR-targeted therapies, including surgical or chemical cas-
tration and androgen antagonists (22–27). Normal and
malignant prostate epithelial cells appear to redirect andro-
gen/AR signaling to regulate different sets of genes via teth-
ering proteins that bind AR to chromatin (16, 28–31).
Therefore, developing drugs that disrupt interactions of AR
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with a tethering protein required exclusively for growth is an
attractive approach for overcoming resistance to current
AR-targeted therapies and would also obviate the need for
androgen ablation.
We have previously reported that the ETS family transcrip-
tion factor ELK1 is essential for growth in PCa cells that are
either dependent on androgen or independent of hormone but
still dependent on the AR (31). In contrast, ELK1 was not
required for growth in AR-negative PCa cells. In PCa cells,
ELK1 is required wholly or in part for activation by andro-
gen/AR of27% of target genes, and these genes are enriched
for clusters supporting cell cycle progression and mitosis (31).
Promoter activation analyses, mammalian two-hybrid assays,
and chromatin immunoprecipitation studies have indicated
that ELK1 recruits AR as a transcriptional co-activator (31).
Other investigators have extended these studies to demonstrate
that ELK1 is similarly required for androgen-dependent growth
of bladder cancer (32, 33). Moreover, chromatin sites of AR
binding are highly enriched for ELK1 binding DNA cis-ele-
ments (34).
ELK1 belongs to the ternary complex factor subfamily of ETS
proteins that characteristically bind to purine-rich GGA core
sequences (35). ELK1 is activated through hyper-phosphoryla-
tion by ERK to transiently activate immediate early genes in
association with the serum-response factor (SRF) (35–39).
Accordingly, ELK1 is one of many substrates of ERK1/2 that
have variable types and combinations of recognition motifs for
ERK (40–42). In the absence of hyper-phosphorylation, ELK1
is in a repressive association with many genes (43). However,
ELK1 is expressed in the clinical spectrum of prostate tumors
(44), and in PCa cells the activation of AR target growth genes
through ELK1 was constitutive and did not entail hyper-phos-
phorylation or activation of immediate early genes (31). In this
study, we now elucidate the physical basis for the interaction
between ELK1 and AR in the context of growth dependence of
PCa cells on ELK1.
Results
Role of the Amino-terminal A/B Domain of AR in Functional
Interactions with ELK1—AR includes the following: (i) an ami-
no-terminal A/B domain containing ligand-independent
transcriptional activation functions (AF1 and AF5); (ii) a car-
boxyl-terminal region (E and F domains) containing the
ligand binding pocket and a ligand-dependent activation func-
tion (AF2); and (iii) internal DNA binding and hinge domains
(C and D domains) (Fig. 1A). Typically (e.g. in LNCaP cells), the
binding of androgen is necessary for AR to localize in the
nucleus, to associate with classical androgen-response ele-
ments (AREs), and to activate its gene targets. However, AR has
splice variants with carboxyl-terminal truncations that remove
the ligand binding pocket; such variants are known to activate
growth genes and support growth of PCa cells in a hormone-
independent manner. Therefore, we tested the ability of the
A/B domain of AR to induce ELK1-dependent gene activation.
In contrast to full-length AR, the AR A/B domain does not
require bound hormone for nuclear localization.
We first used aminimal TATA-dependent promoter lucifer-
ase construct in which two ELK1-binding cis-elements were
placed upstream of the TATA box ((ELK1)2-TATA-LUC). This
construct was transfected along with an expression plasmid for
either the full-length AR or the N-terminal A/B domain of AR
into AR-negative HeLa cells. The full-length AR was able to
activate the promoter in an androgen-dependent manner (Fig.
1B). In contrast, the A/B domain activated the promoter to a
comparable extent both in the presence and in the absence of
hormone (Fig. 1B). When the cells were transfected with the
minimal promoter construct in which the ELK1-binding ele-
ments were substituted with a canonical ARE, promoter activa-
tion only occurred through the full-length AR and in the
presence of androgen (Fig. 1C). Western blotting analysis con-
firmed expression of both the full-length AR and AR(A/B) in
the transfected cells (Fig. 1D).
Next, we compared the abilities of AR(A/B) and the full-
length AR to activate genes (CDCA3,CDCA5, CDC6, andDTL)
previously shown to be activated by AR in an ELK1-dependent
manner (31). We also tested for activation of genes (PRKCA,
TMPRSS2, and KLK3) known to be activated by androgen
(R1881) in an ARE-dependent manner. Androgen activated
both classes of target genes in LNCaP cells, which express full-
length AR (Fig. 1E). However, when AR(A/B) was ectopically
expressed in LNCaP cells in the absence of androgen (Fig. 1F,
inset), only the ELK1-dependent target genes were activated
(Fig. 1F). This result demonstrates that theA/B domain of AR is
able to recapitulate ELK1-dependent gene activation by andro-
gen plus AR.
Next, we testedwhether theA/Bdomain ofAR could support
hormone-independent growth in LNCaP cells. AR(A/B) was
ectopically expressed in LNCaP cells by lentiviral transduction,
and control cells were infected with non-expressing lentivirus
(Fig. 1G, inset). Growth of the control cells was dependent on
androgen (Fig. 1G). The A/B domain of AR was capable of sup-
porting androgen-independent cell growth, albeit less robustly
than androgen (Fig. 1G).
Collectively, the data in Fig. 1 demonstrate that the amino-
terminal A/B domain of AR is adequate for cooperation with
ELK1 and for ELK1-dependent transcriptional activation. This
hormone-independent action of the A/B domain is associated
with partial recapitulation of androgen-dependent growth
induced by full-length AR. The A/B domain may represent the
minimal structural unit of AR that is required for synergizing
with ELK1.
Mapping the Region(s) in ELK1 Required for Association with
AR(A/B)—ELK1 consists of several functional domains. The
amino terminus comprises the A domain encompassing the
ETS DNA binding domain (45). The B domain interacts with
SRF and directs ternary complex formation (46). The C domain
resides at the carboxyl terminus of the protein and regulates
activation through phosphorylation by mitogen-activated pro-
tein kinases (MAPKs). The D domain is a docking site for
MAPKs. There is also an additional MAPK-docking site within
the C domain, known as the DEF (docking site for ERK, FXFP)
motif (47–49). Segments of ELK1 that are required for associ-
ation with the AR A/B domain were mapped using a mamma-
lian two-hybrid assay. For the two-hybrid assay, we used HeLa
cells in which a minimal promoter-luciferase reporter con-
struct with Gal4 elements upstream of the TATA box (GAL4-
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TATA-LUC) was stably integrated. These cells also stably
expressed the AR(A/B)-VP16 fusion protein. The recombinant
HeLa cells were transfected with Gal4-ELK1 fusion constructs
in which the DNA binding domain (amino acids 1–86) was
replaced by that of Gal4. The reporter readout was used to
assess the ability of the Gal4-ELK1 fusion proteins to associate
with AR(A/B)-VP16. In parallel, HeLa cells stably expressing
GAL4-TATA-LUC alone were co-transfected with each one of
the Gal4-ELK1 constructs and an expression plasmid for a con-
stitutively active mutant of MEK1 (CA-MEK1). Activation of
GAL4-TATA-LUC by CA-MEK1 entails phosphorylation and
functional association of ERK1/2 with Gal4-ELK1; therefore,
FIGURE 1.Adequacy of the A/B domain of AR for functional interactions of ARwith ELK1. A shows a schematic for the organization of functional domains
inAR. TheA/Bdomain is the amino-terminal domain (NTD), which contains the ligand-independent activation functionsAF1 andAF5. TheCdomain comprises
the DNA binding domain (DBD) adjacent to a hinge region (D). The E domain encompasses the ligand binding domain (LBD) and the ligand-dependent
activation function, AF2. The F domain represents the carboxyl-terminal domain. B and C, hormone-depleted HeLa cells were transfectedwith an ELK1-driven
minimal promoter-luciferase reporter ((ELK1)2-TATA-LUC) (B) or with an androgen-response element-drivenminimal promoter-luciferase reporter (ARE-TATA-
Luc) (C) and co-transfected with expression plasmids for the AR A/B domain, full-length AR, or the plasmid vector control. The cells were treated with either
testosterone (10 nM) or vehicle at the time of transfection. Luciferase activity wasmeasured in the cell lysates 48 h post-transfection.D shows aWestern blot of
lysates fromcells transfectedwith expressionplasmids for either the full-lengthARor theARA/Bdomain and treatedwith either testosterone (10nM) or vehicle
for 48 h and probed using an antibody to the amino-terminal domain of AR or with antibody to GAPDH (loading control). E, hormone-depleted LNCaP cells
were treated with R1881 (1 nM) or vehicle for 48 h. Total RNA from the cells was used to quantify mRNA levels for the indicated genes that were known to be
either ELK1-dependent or ARE-dependent for activation by AR. F, hormone-depleted LNCaP cells transduced using lentivirus expressing either the AR A/B
domain or with control lentivirus. Cells were harvested 72 h after infection. Total RNA from the cells was used to quantify mRNA levels for the indicated genes
that were known to be either ELK1-dependent or ARE-dependent for activation by AR. The inset shows cell lysates probed by Western blotting using an
antibody to the amino-terminal domain of AR or with antibody to GAPDH (loading control). G, hormone-depleted LNCaP cells transduced using lentivirus
expressing either the AR A/B domain or with control lentivirus. After 72 h, cells were plated in 96-well plates, and cell growthwasmonitored by theMTT assay.
The vector control cellswere treatedwith R1881 (1 nM) or vehicle 24h after plating. The inset showsWesternblotting analysis of cell lysates, 72 hpost-infection,
using antibody to the amino-terminal domain of AR orwith antibody to GAPDH (loading control). For all transfections, a Renilla luciferase reporter was used as
the control for transfection efficiency. In all panels, the error bars represent standard deviation of experimental triplicates. *, p 0.001.
Interactions of the Androgen Receptor and ELK1
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this parallel test probes the ability of each Gal4-ELK1 deletion/
mutation construct to associate with and become activated by
ERK1/2.
First, Gal4-ELK1 constructs containing progressive deletions
beginning from the amino terminuswere tested in the two-hybrid
assay (Fig. 2A). Expression of the transfected constructs was con-
firmedbyWesternblotting,usingantibody to theGal4DNAbind-
ing domain (Fig. 2A, inset). The reporter assay values were similar
to the full-length construct for deletions topositions 187, 261, 287,
and 297. However, there was virtually a complete loss of reporter
activity fordeletions topositions317,327,337,367, and397.These
resultsmap an element required for association of AR(A/B) to the
region downstream of amino acid residue 297 of ELK1 (Fig. 2, A
and schematic in C). The parallel experiment testing activation of
the Gal4-ELK1 constructs by CA-MEK1, showed a virtually iden-
tical pattern of activity (Fig. 2B, inset), a result that is consistent
with the position of the D-box region beginning at residue 312
(schematic in Fig. 2C).
Next, Gal4-ELK1 constructs containing progressive dele-
tions beginning from the carboxyl terminus were tested in the
two-hybrid assay (Fig. 3A). Again, expression of the transfected
constructs was confirmed by Western blotting (Fig. 3A, inset).
FIGURE 2. Mapping ELK1 polypeptide segments required for co-activation by AR(A/B) by amino-terminal deletion analysis. A shows data obtained
using recombinant HeLa cells generated by stably transducing a minimal promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC)
and also with a vector expressing the AR A/B domain fused to the VP16 transactivation domain. Cells were transfected with plasmids expressing Gal4 fusion
proteins of ELK1. The fusion constructs substituted the Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA binding domain of ELK1. Within this fusion
construct, a series of amino-terminal deletions were made, as indicated in the schematic in A. Forty eight hours after transfection with the various Gal4-
ELK1fusion constructs, cells were harvested by preparing lysates formeasurement of luciferase activity. The promoter activity shownon the y axis required the
presence of the AR A/B domain as knocking downAR(A/B) expression in the same cells transfectedwith full-length Gal4-ELK1 decreased the promoter activity
to the basal value shown in the figure for Gal4-DBD alone. The inset shows cell lysates probed by Western blotting with antibodies against Gal4 or GAPDH
(loading control). B shows data obtained using recombinant HeLa cells generated by stably transducing only GAL4-TATA-LUC. The cells were transfected with
each of the Gal4-ELK1 fusion constructs used in A and co-transfected with an expression plasmid for a constitutively activemutant of MEK1 or with the vector
control. Forty eight hours after transfection with the various Gal4-ELK1 fusion constructs, cells were harvested by preparing lysates for measurement of
luciferase activity. The inset shows cell lysates probedbyWestern blottingwith antibodies against Gal4 or GAPDH (loading control).C shows a schematic of the
domain organization of ELK1; here, the amino-terminal deletion mapping of an ELK1 polypeptide segment encompassing residues required for association
with AR(A/B) (data from A) is represented by gray shading. For all transfections, a Renilla luciferase reporter was used as the control for transfection efficiency.
In all panels, the error bars represent standard deviation of experimental triplicates. *, p 0.001.
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The reporter assay values were similar to the full-length con-
struct for the deletion made at position 397, but it was lost for
deletions to positions 387, 377, and 367. These results map an
element required for association of AR(A/B) to the region
upstream of amino acid residue 397 of ELK1 (Fig. 3, A and
schematic in C). The parallel experiment testing activation of
theGal4-ELK1 constructs byCA-MEK1 again showed the same
pattern (Fig. 3B, inset). This result is consistent with the posi-
tion of the DEFmotif, which serves as an additional ERK-dock-
ing site (schematic in Fig. 3C).
Additionally, we made and tested the effects of a series of
short overlapping internal deletions within Gal4-ELK1 (Fig.
4A) using the two-hybrid assay. The internal deletions covered
segments flanking andwithin the regionmapped above by ami-
no- and carboxyl-terminal deletion analyses. Expression of the
Gal4-ELK1 constructs was confirmed byWestern blotting (Fig.
4A, inset). As shown in Fig. 4A, the reporter assay values for the
constructs clearly fell into the following two groups: those cor-
responding to the activity of the full-length construct, and those
approaching the background value obtained by transfecting the
Gal4 DNA binding domain alone. Based on these data, we were
able to confirm and further bracket peptide motifs required for
association of AR(A/B) to within the amino acid sequences
307–350 and 372–397. Activation of the Gal4-ELK1 internal
deletion constructs by CA-MEK1 followed a similar pattern
except for the deletion 351–371, which reduced activation by
CA-MEK1 but not association with AR(A/B)-VP16 (Fig. 4B,
inset). These results are again consistent with the locations of
the ERK-docking sites in ELK1 (D box and DEF motif) (sche-
matic in Fig. 4C). As residues 351–371 lie within the transacti-
vation domain (domain C, residues 351–399) of ELK1 (sche-
matic in Fig. 4C) and include two ERK phosphorylation sites
FIGURE 3.Mapping ELK1 polypeptide segments required for co-activation by AR(A/B) by carboxyl-terminal deletion analysis. A shows data obtained
using recombinant HeLa cells generated by stably transducing a minimal promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC)
and also with a vector expressing the AR A/B domain fused to the VP16 transactivation domain. Cells were transfected with plasmids expressing Gal4 fusion
proteins of ELK1. The fusion constructs substituted the Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA binding domain of ELK1. Within this fusion
construct, a series of carboxyl-terminal deletionsweremade, as indicated in the schematic in A. Forty eight hours after transfectionwith the various Gal4-ELK1
fusion constructs, cells were harvested by preparing lysates for measurement of luciferase activity. The promoter activity shown on the y axis required the
presence of the AR A/B domain because knocking down AR(A/B) expression in the same cells transfected with full-length Gal4-ELK1 decreased the promoter
activity to the basal value shown in the figure for Gal4-DBD alone. The inset shows cell lysates probed by Western blotting with antibodies against Gal4 or
GAPDH (loading control). B shows data obtained using recombinant HeLa cells generated by stably transducing only GAL4-TATA-LUC. The cells were trans-
fectedwith each of the Gal4-ELK1 fusion constructs used in A and co-transfectedwith an expression plasmid for a constitutively activemutant ofMEK1 orwith
the vector control. Forty eight hours after transfectionwith the variousGal4-ELK1 fusion constructs, cellswereharvestedbypreparing lysates formeasurement
of luciferase activity. The inset shows cell lysates probed byWestern blotting with antibodies against Gal4 or GAPDH (loading control). C shows a schematic of
the domain organization of ELK1; here, the carboxyl-terminal deletionmapping of an ELK1 polypeptide segment encompassing residues required for associ-
ation with AR(A/B) (data from A) is represented by gray shading. For all transfections, a Renilla luciferase reporter was used as the control for transfection
efficiency. In all panels, the error bars represent standard deviation of experimental triplicates. *, p 0.001.
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(39), its requirement for optimal activation of ELK1 by CA-
MEK1 was anticipated.
To further refine themapping data for themotif required for
association of AR(A/B) within the ELK1 polypeptide segment
307–350, we made additional deletions of residues 331–340
and 341–350 (Fig. 5A). Western blotting confirmed expression
of the constructs (Fig. 5B, inset). Neither deletion reduced the
reporter activity in the two-hybrid assay (Fig. 5B), thus fur-
ther bracketing the upstream element required for associa-
tion of AR(A/B) to within amino acid residues 307–330.
These internal deletions also had no effect on activation of
Gal4-ELK1 by CA-MEK1 (Fig. 5C, inset). Finally, we tested
whether the FQFP motif (FXFP motif) and the D-box region
(residues 308–321), both of which direct ERK docking to
ELK1, were also required for the association of AR(A/B) to
ELK1. We tested a Gal4-ELK1 construct in which the FQFP
motif was mutated to FQLA, a Gal4-ELK1 construct in
which the D-box region (ELK1 residues 308–321) was
FIGURE 4. Mapping ELK1 polypeptide segments required for co-activation by AR(A/B) by internal deletion analysis. A shows data obtained using
recombinant HeLa cells generated by stably transducing a minimal promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC) and
also with a vector expressing the AR A/B domain fused to the VP16 transactivation domain. Cells were transfected with plasmids expressing Gal4 fusion
proteins of ELK1. The fusion constructs substituted the Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA binding domain of ELK1. Within this fusion
construct, a series of internal deletions were made, as indicated in the schematic in A. Forty eight hours after transfection with the various Gal4-ELK1 fusion
constructs, cells were harvested by preparing lysates for measurement of luciferase activity. The promoter activity shown on the y axis required the presence
of the AR A/B domain because knocking down AR(A/B) expression in the same cells transfected with full-length Gal4-ELK1 decreased the promoter activity to
thebasal value shown in the figure forGal4-DBDalone. The inset shows cell lysatesprobedbyWesternblottingwith antibodies againstGal4orGAPDH (loading
control).B showsdataobtainedusing recombinantHeLa cells generatedby stably transducingonlyGAL4-TATA-LUC. The cellswere transfectedwitheachof the
Gal4-ELK1 fusion constructs used inA and co-transfectedwith anexpressionplasmid for a constitutively activemutant ofMEK1orwith the vector control. Forty
eighthours after transfectionwith thevariousGal4-ELK1 fusionconstructs, cellswereharvestedbypreparing lysates formeasurementof luciferaseactivity. The
inset shows cell lysates probed byWestern blottingwith antibodies against Gal4 or GAPDH (loading control). C shows a schematic of the domain organization
of ELK1; here, the deletion mapping of two ELK1 polypeptide segments encompassing residues required for association with AR(A/B) (data from Figs. 3A, 4A,
and5A) is representedby gray shadingof the two segments. For all transfections, a Renilla luciferase reporterwas used as the control for transfection efficiency.
In all panels, the error bars represent standard deviation of experimental triplicates. *, p 0.001.
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deleted, and a Gal4-ELK1 construct with both lesions. All
three resulted in loss of function of AR(A/B)-VP16 in the
two-hybrid assay (Fig. 5D, inset), mirroring the loss of acti-
vation by CA-MEK1 (Fig. 5E, left and right).
Collectively, the data from Figs. 2 to 5 identify two peptide
motifs in ELK1 that are both essential for its association with
the A/B domain of AR. The pattern of retention or loss of asso-
ciation with AR(A/B) due to the various deletions/mutations in
ELK1 mirrored the pattern for activation by ERK with one
exception, i.e. a deletion within the transactivation domain of
ELK1, which disrupted activation by ERK but did not affect
association with AR(A/B). The two ELK1 motifs required for
association with AR(A/B) equate to the two ERK-docking sites
in ELK1.
FIGURE 5. Further refinement of the mapping of ELK1 motifs required for co-activation by AR(A/B). A shows the ELK1 polypeptide sequence. The
bracketed segments indicate the two segments that were mapped from the deletion analyses in Figs. 3–5 as regions containing residues essential for the
association of ELK1with AR(A/B). The boxed segments denote the D-domain of ELK1 and the FXFPmotif of ELK1. The segments in bold font represent peptides
that were deleted for further mapping in B and C. B and D show data obtained using recombinant HeLa cells generated by stably transducing a minimal
promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC) and also with a vector expressing the AR A/B domain fused to the VP16
transactivation domain. Cells were transfectedwith plasmids expressing Gal4 fusion proteins of ELK1. The fusion constructs substituted the Gal4 DNAbinding
domain (Gal4-DBD) for theETSDNAbindingdomainof ELK1.Within this fusion construct, the indicated internal deletionsormutationsweremade, as indicated
in the schematics in B and D. Forty eight hours after transfection with the various Gal4-ELK1 fusion constructs, cells were harvested by preparing lysates for
measurement of luciferase activity. The promoter activity shown on the y axis required the presence of the AR A/B domain as knocking down AR(A/B)
expression in the same cells transfectedwith full-length Gal4-ELK1 decreased the promoter activity to the basal value shown in the figure for Gal4-DBD alone.
The insets in B andD show cell lysates probed byWestern blottingwith antibodies against Gal4 or GAPDH (loading control). C and E show data obtained using
recombinant HeLa cells generated by stably transducing onlyGAL4-TATA-LUC. The cells were transfectedwith each of the Gal4-ELK1 fusion constructs used in
B and D, respectively, and co-transfected with an expression plasmid for a constitutively active mutant of MEK1 or with the vector control. Forty eight hours
after transfection with the various Gal4-ELK1fusion constructs, cells were harvested by preparing lysates for measurement of luciferase activity. The insets in C
and E show cell lysates probed byWestern blotting with antibodies against Gal4 or GAPDH (loading control). For all transfections, a Renilla luciferase reporter
was used as the control for transfection efficiency. In all panels, the error bars represent standard deviation of experimental triplicates. *, p 0.001.
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ELK1 Motifs Required for Association with the AR A/B
Domain Participate inHormone-inducedActivation of ELK1 by
Full-length AR—To further validate the mapping of ELK1
motifs required for association with AR, it was necessary to
confirm that the mapping data obtained above by the mamma-
lian two-hybrid assay using AR(A/B)-VP16 applies to the full-
length AR. For this purpose we tested Gal4-ELK1 fusion con-
structs with deletions and mutations that were indicative for
bracketing the binding sites forAR(A/B) (Fig. 6A). Each of these
constructs, as well as control constructs, was co-transfected
with full-length AR in recombinant HeLa cells in which the
GAL4-TATA-LUC promoter-reporter was stably integrated.
The cells were treated with testosterone or the vehicle control
beginning at the time of transfection. Androgen activated the
promoter only in cells transfected with Gal4-ELK1 constructs
that were found in the preceding sections to have the ability to
bind AR(A/B) (Fig. 6A). It was confirmed that both AR and the
appropriate Gal4-ELK1 construct were expressed in the trans-
fected cells, as observed by Western blotting using antibody to
either Gal4 or AR (Fig. 6B).
To complement the above data, we co-expressed in HeLa
cells AR and WTELK1 or AR and a mutant of ELK1 in which
either one of the two ERK-docking sites was disrupted. AR and
WTELK1 co-immunoprecipitated in these cells; however,
when ELK1 was mutated at either one of its two ERK-docking
sites, it was unable to co-immunoprecipitate with AR (Fig. 6C).
These results demonstrate that functional association of the
full-length AR with ELK1 (or transcriptional co-activation of
ELK1 by AR) requires the same ELK1 motifs as those mapped
for the binding of AR(A/B) to ELK1.
Influence of SRF on the Interaction of AR with ELK1—Func-
tional interactions between AR and ELK1 could be influenced
by the association of ELK1 with its DNA-binding partner SRF.
To explore this possibility, we first used recombinantHeLa cells
in which a minimal promoter-luciferase reporter construct
with Gal4 elements upstream of the TATA box (GAL4-TATA-
LUC) was stably integrated in the chromatin. The cells also
stably expressed full-length AR and the Gal4-ELK1(87–428)
fusion protein. Induction of reporter luciferase activity by tes-
tosterone wasmeasured to quantify the binding of AR to ELK1.
FIGURE 6. ELK1motifs required for co-activation by full-length AR. A shows data obtained using recombinant HeLa cells generated by stably transducing
a minimal promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC). Cells were plated in hormone-depleted media and co-trans-
fectedwith expressionplasmids for the indicatedGal4-ELK1 fusionproteins and anexpressionplasmid for full-lengthAR. The fusion constructs substituted the
Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA binding domain of ELK1. At the time of transfection, the cells were treatedwith testosterone (10 nM) or
vehicle control. Forty eighthours after transfection, cellswereharvestedbypreparing lysates formeasurementof luciferaseactivity.B showscell lysatesprobed
byWestern blottingwith antibodies against Gal4, AR, or GAPDH (loading control). C shows data on co-immunoprecipitation of ectopic AR and ectopic ELK1 or
ELK1mutants fromHeLa cell lysates. HeLa cellswere transfectedwith the expressionplasmid for AR and co-transfectedwith an expressionplasmid forWTELK1
or one of two ELK1 mutants, ELK1308–321 and ELK1 FxLa. The lysates were immunoprecipitated (IP) using either antibody to AR or a negative control. The
immunoprecipitates were probed by Western blotting using antibody to either AR or ELK1 as indicated. *, p 0.01.
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In these cells, lentiviral transduction with shRNA against SRF
resulted in knocking down SRF at both the mRNA and protein
levels compared with control shRNA (Fig. 7A and inset).
Knockdown of SRF significantly increased testosterone-in-
duced luciferase activity (Fig. 7B).
As a complementary approach, we used recombinant HeLa
cells that stably expressed the AR(A/B) domain fused to the
VP16 transactivation domain (AR(A/B)-VP16). Additionally,
the GAL4-TATA-LUC promoter-reporter was stably inte-
grated in the chromatin. In these cells, we examined the effect
of SRF knockdown on the hormone-independent activation of
ELK1 by AR(A/B)-VP16. Cells were transduced with shRNA
against SRF or with control shRNA followed by transfection
with the Gal4-ELK1 fusion construct or with the Gal4 control
vector. SRF shRNA substantially decreased both SRF mRNA
and protein (Fig. 7C and inset) and increased the luciferase
reporter activity 3-fold compared with cells transduced with
control shRNA (Fig. 7D). Taken together, these results demon-
strate that SRF is not required for activation of ELK1 by AR;
rather, SRF may hinder optimal ELK1-dependent transcrip-
tional activation by AR.
Influence of ERK1/2 on the Interaction of ARwith ELK1—The
requirement for MAPK-docking motifs in ELK1 suggested the
possibility that the functional association of AR with ELK1
could involve ERKs, the classical ELK1-activating protein
kinases, as an essential component of the ELK1-AR complex.
As a first test, we used recombinantHeLa cells stably expressing
AR(A/B)-VP16 in which the GAL4-TATA-LUC promoter-re-
porter was also stably integrated. These cells were co-trans-
fected with siRNAs against ERK1 and ERK2 or transfected with
control siRNA. ERKmRNAs and proteins were depletedwithin
48 h of siRNA transfection compared with the control siRNA
(Fig. 7E, top and bottom). Following knockdown of ERKs, the
cells were transfected again, this time with expression plasmid
for the Gal4-ELK1 fusion protein or the control Gal4 vector. In
parallel, cells were also co-transfected with Gal4-ELK1 and the
expression plasmid for CA-MEK1. The reporter luciferase
activity was measured 24 h following the second transfection
(72 h following the first transfection), while the knockdown of
ERKs persisted (Fig. 7E, top and bottom). The synergistic acti-
vation of the promoter-reporter by AR and ELK1 was unaf-
fected by the combined depletion of ERK1 and ERK2 (Fig. 7F).
In contrast, the CA-MEK-induced hyper-activation of the pro-
moter was abrogated by depletion of ERK1 and ERK2, decreas-
ing the promoter activation to the level observed for cells only
expressing AR(A/B) and Gal4-ELK1 (Fig. 7F).
Second, we tested whether AR(A/B) would compete with
ERKs as activators of ELK1.We used recombinantHeLa cells in
which the GAL4-TATA-LUC promoter-reporter was stably
integrated and that also stably expressed the Gal4-ELK1 fusion
protein. As expected, in these cells ectopic expression of CA-
MEK1 strongly stimulated expression of the luciferase reporter
(Fig. 7G). However, co-expression of AR(A/B) decreased the
promoter activation (Fig. 7G), indicating that AR interferes
with hyper-activation of ELK1 by ERKs.
In a third approach, the effect of ERK activity on the interac-
tion between ELK1 and AR was tested using HeLa cells co-
transfected with the (ELK1)2-TATA-luc reporter and an
expression plasmid for either AR(A/B) or CA-MEK1. The
(ELK1)2-TATA-luc promoter was responsive to the endoge-
nous ELK1 in the cells. Following the transfections, the cells
were treated with the MEK inhibitor, trametinib. As expected,
MEK-induced activation of the promoter was inhibited by tra-
metinib (Fig. 7H). In contrast, trametinib did not affect activa-
tion of the promoter by AR(A/B). The results from the comple-
mentary approaches of depletion and inhibition of ERK1/2 and
competition betweenMEK1 andAR(A/B) as activators of ELK1
all demonstrate that the functional interaction of AR and ELK1
is insensitive to the expression or activation status of ERKs. The
data indicate that the association of ARwith ELK1 occurs inde-
pendently of ERK1 and ERK2.
Direct Binding of AR and ELK1—The studies above indicate
that the classical binding partners of ELK1, i.e. SRF andERK1/2,
interferewith rather than facilitate functional association of AR
with ELK1. Therefore, to test whether the association of AR
with ELK1 could be due to direct binding, we used surface plas-
mon resonance (SPR). Purified AR (Abcam, Cambridge, MA)
was immobilized as the “ligand.” His-tagged ELK1 and His-
tagged mutant ELK1, in which both the D-box and the DEF
motif were disrupted (308–321, F397L, and P398A), were
affinity-purified to85% (Fig. 8A) and used as the analyte. The
binding kinetics for ELK1 was determined at concentrations of
0, 5, 10, 20, 40, 80, and 160 nM (Fig. 8B). Bovine serum albumin
was used as the negative control. Kinetic constants were evalu-
ated using the BIAevaluation software. The equilibrium disso-
ciation constant for the AR-ELK1 interaction was determined
to be 1.9  108 M. When the mutant ELK1 was used as the
analyte at a concentration of 100 nM, the average response units
from triplicate measurements was reduced by90% compared
with 100 nM ELK1 (Fig. 8C). The relatively high affinity of bind-
ing of purified preparations of AR and ELK1 strongly supports
the concept that the in situ interactions of the two proteins are
due to direct binding. Moreover, loss of this binding due to
disruption of the ERK-docking sites in ELK1 strongly indicates
that these are also the docking sites for AR.
Relevance of the Physical Association of ELK1 and AR to
Androgen-dependent Cell Growth—Previous studies using
ELK1 depletionmethods have demonstrated that both prostate
and bladder cancer cells require ELK1 for androgen-dependent
growth (31–33). However, they did not test the physiological
effect of disrupting the association of ELK1withAR. To disrupt
the hormone-dependent association of AR and ELK1 in situ
without disrupting the ability of ELK1 to bind to DNA, we used
an ELK1 mutant lacking the D-box region (amino acids 308–
321) that should competewith endogenous ELK1 for binding to
chromatin. We tested whether the mutant ELK1 would pro-
duce a dominant-negative effect on androgen-dependent
growth. LNCaP cells were transducedwith lentiviral expression
vectors for either ELK1 or the ELK1308–321mutant (Fig. 8D,
inset). Ectopic overexpression of ELK1 did not appreciably
influence androgen (R1881)-dependent growth compared with
the vector-transduced control (Fig. 8D). In contrast, ectopic
overexpression of the ELK1308–321 mutant showed a
dominant-negative effect by inhibiting hormone-dependent
growth. To confirm that the dominant-negative effect of this
ELK1308–321 on androgen-dependent growth was not due
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FIGURE 7. Effect of depleting SRF or ERK1/2 on the interactions of ARwith ELK1. A and B show data obtained using recombinant HeLa cells generated by
stably transducing a minimal promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC) and also with vectors expressing AR and a
Gal4-ELK1 fusion construct in which the Gal4 DNA binding domain was substituted for the ETS DNA binding domain of ELK1. The cells were depleted of
hormone and then transducedwith shRNA against SRF or a non-targeted control shRNA using lentivirus. Seventy two hours after infection, cells were treated
with testosterone (10 nM) or vehicle for a further 48 h. The cells were then harvested to quantify SRFmRNA (A) or for Western blotting analysis using antibody
to SRF or to GAPDH (loading control) (A, inset) or for luciferase activity (B). C and D show data obtained using recombinant HeLa cells generated by stably
transducing GAL4-TATA-LUC and also a vector expressing the AR A/B domain fused to the VP16 transactivation domain (AR(A/B)-VP16). The cells were
transduced with shRNA against SRF or a non-targeted control shRNA using lentivirus. Seventy two hours after infection, the cells were transfected with
expression plasmid for the Gal4-ELK1 fusion protein. Forty eight hours later, the cells were harvested to quantify SRFmRNA (C) or forWestern blotting analysis
using antibody to SRF or to GAPDH (loading control) (C, inset) or to measure luciferase activity (D). E–G show data obtained using the recombinant HeLa cells
with stably incorporated GAL4-TATA-LUC and stably expressing the AR(A/B)-VP16 fusion protein. Cells were transfected with a mixture of siRNA against ERK1
and ERK2 or with control non-targeted siRNA. After 48 h of transfection, the cells were harvested to quantify mRNAs for ERK1 and ERK2 (E) or for Western
blotting analysis using antibody to ERK1/2 or to GAPDH (loading control) (E, below); the remaining cells were transfected for a second timewith the Gal-4ELK1
expression plasmid or the control vector plasmid or the plasmid for constitutively active mutant of MEK1 (F). After a further 24 h, the cells were harvested to
quantify mRNAs for ERK1 and ERK2 (E) or for Western blotting analysis using antibody to ERK1/2 or to GAPDH (loading control) (E, below) or to measure
luciferase activity (F). H, HeLa cells were co-transfected with an ELK1-drivenminimal promoter-luciferase reporter ((ELK1)2-TATA-LUC) and expression plasmid
for either AR(A/B) or constitutively active MEK1 or control vector plasmid. The cells were treated with trametinib (1M) or vehicle for 48 h beginning with the
timeof transfection. Luciferase activitywasmeasured in the cell lysates. For all transfections, aRenilla luciferase reporterwasusedas the control for transfection
efficiency. In all panels, the error bars represent standard deviation of experimental triplicates. *, p 0.001; **, p 0.001.
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to dependence on activation of ELK1 by ERK, we demonstrate
that LNCaP growth is insensitive to inhibition of MEK by tra-
metinib (Fig. 8E); as a control in Fig. 8E, the AKT inhibitor
AKTi-1/2 completely inhibited androgen-dependent growth.
These results further validate the model that docking of AR on
ELK1 is an essential component of growth signaling by andro-
gen/AR in prostate cancer cells.
Synergy between the Splice Variant AR-V7 and ELK1 and
AR-V7-dependent Cell Growth—The ability of the amino-ter-
minal A/B domain of AR to synergize with ELK1 suggested that
AR-V7, the major splice variant of AR, would most likely also
synergize with ELK1. To test this possibility, we co-transfected
the (ELK1)2-TATA-luc promoter-reporter construct with an
expression plasmid for AR-V7 and WTELK1 into the AR-neg-
ative HeLa cells. Ectopic AR-V7 activated the promoter-driven
luciferase activity well above the basal level presumably associ-
ated with endogenous ELK1 (Fig. 9A). Similarly, when the
GAL4-TATA-LUC promoter was co-transfected with Gal4-
ELK1 and AR-V7, there was strong induction of promoter
activity (Fig. 9B). Western blotting analysis confirmed expres-
sion of the AR-V7 construct in both cases (Fig. 9C).
We have previously demonstrated that ELK1 is necessary for
androgen/AR-dependent growth of prostate cancer cells. To
test whether prostate cancer cells that are dependent onAR-V7
FIGURE 8. Direct binding of ELK1 and AR and the effect of disrupting docking sites in ELK1 on AR binding and androgen-dependent cell growth. A
shows SDS-PAGE of purified His-tagged ELK1 protein and His-tagged ELK1 protein mutated (ELK1 mut) in both D-box (308–321) and DEFmotif. The protein
bandswere visualized byCoomassie Blue staining and estimated to be85%pure andused in the SPR experiments below togetherwith purifiedARobtained
commercially. B shows SPR kinetic curves for quantitative analyses of AR binding to His-tagged ELK1. ARwas immobilized on a CM5 sensor chip, and ELK1was
diluted in a series of concentrations (0, 5, 10, 20, 40, 80, and 160 nM). The results were normalized by subtracting the SPR response (RU) for buffer alone or BSA
and performed in duplicate. C shows SPR kinetic curves for quantitative analyses of AR binding to His-tagged mutant ELK1. AR was immobilized as in B, and
ELK1 ormutant ELK1was used at 100 nM. The kinetic curves for triplicate determinations are shown.D, hormone-depleted LNCaP cells were transduced using
lentivirus expressing either the WTELK1, or ELK1(308–321), or with control lentivirus. After 72 h, cells were plated in 96-well plates, and cell growth was
monitored by theMTT assay. Twenty four hours after plating, the cells were treatedwith R1881 (1 nM) or vehicle for a further 72 h. The inset inD showsWestern
blotting analysis of cell lysates, 72 h post-infection, using antibody to ELK1 or with antibody to GAPDH (loading control). The error bars represent standard
deviation of experimental triplicates. *, p 0.001. E,hormone-depleted LNCaP cells were plated in 96-well plates in the presence of R1881 (1 nM) togetherwith
vehicle, trametinib (1M), or AKTi-1/2 (2M).MTT assaywas performed72h later. The error bars represent standard deviation of experimental triplicates. *, p
0.001.
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also depend on ELK1, we used shRNA to deplete ELK1 in
CWR22Rv1 cells, which depend on endogenous AR-V7. Partial
depletion of ELK1 prevented the growth of these cells (Fig. 9D,
top and bottom panels). These results confirm that the AR-V7
splice variant cooperates with ELK1 as a transcriptional co-ac-
tivator in the same manner as AR(A/B) and that ELK1 is also
necessary for AR-V7-dependent growth of prostate cancer
cells.
Discussion
The results of this study elucidate the nature of the interac-
tion of the ligand-independent A/B domain of AR with ELK1
that accounts for the ELK1-dependent transcriptional activity
of AR in PCa cells. Systematic mapping using a mammalian
two-hybrid assay and an extensive series of ELK1 deletion and
point mutants, and confirmatory co-immunoprecipitation
experiments, identified the two ERK-docking motifs (D-box
and DEFmotif) in ELK1 as the elements essential for co-activa-
tion by AR. Nonetheless, the AR synergy with ELK1 is indepen-
dent of ERKs and involves AR binding directly to ELK1. Inter-
actions with ELK1 are required for hormone-dependent
growth of PCa cells and also account for the ability of the AR
A/B domain, as well as the major AR splice variant AR-V7, to
support their hormone-independent growth. Indeed the results
strongly support the view that synergy with ELK1, via AR dock-
ing on ELK1, is a critical component of growth signaling by AR
and AR-V7.
The mammalian two-hybrid mapping data with Gal4ELK1
mutants were clear-cut. Parallel studies using a constitutively
active form of MEK to activate ELK1 demonstrated that the
regions required for co-activation by AR(A/B) precisely coin-
cided with the D-box and DEF motifs in ELK1 (40–42). Acti-
vation was hormone-independent as, in contrast to full-length
AR, the A/B domain is not constrained by the need for ligand
binding to enter the nuclear compartment. Importantly, map-
ping data for the sites of interaction of the ARA/B domain with
FIGURE 9. Functional association of ELK1 and AR-V7 and effect on cell growth. A, HeLa cells were co-transfected with an ELK1-driven minimal promoter-
luciferase reporter ((ELK1)2-TATA-LUC) and expression plasmid for either AR-V7 orWTELK1 or control vector plasmid for 48 h. Luciferase activity wasmeasured
in the cell lysates. For all transfections, a Renilla luciferase reporter was used as the control for transfection efficiency. B, HeLa cells were co-transfected with a
Gal4-driven minimal promoter-luciferase reporter (Gal4-TATA-Luc) and expression plasmid for either AR-V7 or Gal4-ELK1 or control vector plasmid for 48 h.
Luciferase activitywasmeasured in the cell lysates. For all transfections, a Renilla luciferase reporter was used as the control for transfection efficiency. C shows
aWestern blot of HeLa cell lysates corresponding to all of the transfections in A and B,which was probed using an antibody to the amino-terminal domain of
AR or with antibody to GAPDH (loading control).D, top panel shows the effect of depleting ELK1 by lentiviral shRNA transduction on the growth of CWR22Rv1
cellsmonitoredby theMTTassay comparedwith control shRNA. TheWesternblot in thebottompanel showsELK1 shRNA-induceddepletionof ELK1 compared
with control shRNA; GAPDH was probed as the loading control.
Interactions of the Androgen Receptor and ELK1
25994 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 50•DECEMBER 9, 2016
 at U
N
IV
 O
F N
O
TTIN
G
H
A
M
 on M
arch 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ELK1 were entirely recapitulated with full-length AR and con-
firmed by co-immunoprecipitation. There were two notable
differences between co-activation of ELK1byARand activation
byMEK. First, the level of ELK1 transcriptional activity induced
byMEKwas substantially higher than that induced by AR. This
difference in magnitude is associated with the transient nature
of ELK1 activation through the MAPK pathway in contrast to
the constitutive ELK1-dependent activation of growth genes by
AR (31). Second, an intact ELK1 transactivation domain was
essential for activation by MEK but not for co-activation of
ELK1 by AR. This finding indicates that AR only utilizes ELK1
for recruitment to regulatory sites in chromatin to activate
growth genes and that the transcriptional activityper seof ELK1
is unimportant for the ELK1-AR synergy.
Complementary approaches, including one- and two-hybrid
assays, promoter assays, gene knockdown,MEK inhibition, and
competition assays, demonstrated that the classical binding
partners of ELK1 in the ternary complex factor, i.e. SRF and
ERKs (49), are not required for co-activation of ELK1 by AR.
Indeed, SRF and ERKs both appeared to interfere with the
interaction of AR with ELK1. SRF knockdown may release
ELK1 from immediate early gene promoters, which are unre-
sponsive to androgen (31). Similarly, ELK1 recruits ERKs
directly to a subset of target genes (50) suggesting that ERK
competes directly with AR for ELK1 binding. Indeed, SPR con-
firmed binding between ELK1 and AR with a relatively high
affinity (Kd, 1.9 108 M), strongly supporting the premise that
the transcriptional synergy between ELK1 and AR is due to
direct binding. Loss of this binding uponmutational disruption
of the ERK-docking sites in ELK1 equates the ELK1 motifs
required for functional associationwithARwith those required
for direct binding of AR to ELK1.
ETS elements are commonly enriched at or in the vicinity of
AR-binding sites in the chromatin (51, 52), and indeed physical
association of AR has been suggested with ETV1 (53) and ETS1
(51). However, in neither case has the structural binding ele-
ments in either AR or the ETS protein been elucidated. Among
the known DNA-binding proteins that have been suggested to
recruit AR, the interactions of ARwithHoxB13 andC/EBPa are
perhaps the best studied. HoxB13 interacts with theDNAbind-
ing domain of AR (29), whereas C/EBPa did not show a strong
AR domain selectivity for interaction, and its association with
AR involved multiple AR domains (30). Relatively little is
known about the structural basis for non-genomic interactions
of AR and other nuclear receptors with signaling pathways
involvingMAPK, PI3K/Akt, PKC, PLC, andG-protein-coupled
receptors (1). Notable exceptions include the direct or indirect
associations of NRs with the Src homology 2 or 3 domains
where proline-rich motifs in AR and the progesterone receptor
or LXXL motifs in the estrogen receptor are required (54–57).
The relatively large size and multidomain structure of NRs
appear to offer a diversity of binding motifs for interactions
with co-activators and DNA binding transcription factors.
To our knowledge, the functional interaction of AR with
ELK1 is the first demonstration of a nuclear receptor co-opting
protein kinase-docking sites to regulate or constitutively acti-
vate a signaling pathway. The finding that ERK-docking motifs
can recruit AR suggests that AR may adopt similar modes of
interaction in its cross-talkwith other signalingmolecules. Cer-
tainly, by mimicking ERK interactions with docking motifs, AR
may interact with additional substrates of ERK, of which there
are over 50 (40). There is much cross-talk between AR genomic
and non-genomic pathways in prostate cancer. The canonical
pathway for AR signaling requires nuclear translocation of the
ligand-bound receptor to activate transcription and induce
proliferation in PCa cells. Activation of the MAPK phosphory-
lation cascade can be induced through non-genomic pathways
of AR signaling and stimulate cell proliferation. Activated ERK
can phosphorylate AR and its co-activators, and therefore, this
feedback loop of the non-genomic AR signaling may induce
genomic AR signaling in prostate cancer (58, 59). These are
pathways that are well known in the literature pertaining to
PCa; however, these classical genomic and non-genomic AR-
signaling pathways are independent of the AR-tethering mech-
anism and the ability of AR to co-opt the ERK-docking sites in
ELK1 to activate transcription, which are described in this
report.
Overexpression of an ELK1-docking sitemutant inwhich the
ability to associate with AR was disrupted without disrupting
the DNA binding domain had a dominant-negative effect on
androgen-stimulated growth in PCa cells. Thiswas unrelated to
loss of ERK binding in themutant ELK1 as the cells were insen-
sitive to MEK inhibition. As the discrete DNA binding domain
in themutant ELK1was not compromised, themutant presum-
ably still bound to ELK1 elements in the DNA; however,
because the D-box was deleted in the mutant ELK1, our map-
ping data would predict that ARwould not bind to it. The dom-
inant-negative effect of the mutant ELK1 on androgen-stimu-
lated growth is therefore consistent with this prediction. These
observations provide an additional functional link between
recruitment of AR by ELK1 and growth signaling by AR in PCa
cells. The characterization of such discrete AR-interacting
motifs should enable development of small molecule drugs that
bind to those sites and selectively target dysregulated growth
signaling in prostate cancer, while avoiding the global side
effects of androgen ablation.
Experimental Procedures
Cell Culture and Reagents—LNCaP, CWR22Rv1 cells, and
HeLa cell lines were from the American Type Culture Collec-
tion (Manassas, VA); 293FT cells were from Invitrogen. HeLa
cells with a stably integrated minimal promoter-luciferase
reporter containing five upstream Gal4 elements (GAL4-
TATA-LUC) and expressing a Gal4-ELK1 fusion protein in
which the Gal4 DNA binding domain was substituted for the
ETSDNAbinding domain of ELK1were kindly provided byDr.
Johann Hofman (Innsbruck Medical University). These cells
were then stably transduced with a vector expressing the full-
length AR. Recombinant HeLa cells were also generated by sta-
bly transducing GAL4-TATA-LUC and a vector expressing the
AR(A/B) domain fused to the VP16 transactivation domain
(AR(A/B)-VP16). LNCaP cells were routinely grown at 37 °C in
5% CO2 in RPMI 1640 medium supplemented with 10% FBS
(Invitrogen), 100 units/ml penicillin, 100 g/ml streptomycin,
2 mM L-glutamine mixture (Invitrogen), and sodium pyruvate
(1 mM) (Invitrogen). CWR22Rv1 cells were grown in phenol
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red-free RPMI 1640 medium supplemented with 10% FBS
(Invitrogen), 100 units/ml penicillin, 100 g/ml streptomycin,
2 mM L-glutamine mixture (Invitrogen). Parental and recombi-
nant HeLa cells were grown in DMEM supplemented with 10%
FBS and 100 units/ml penicillin, 100g/ml streptomycin, 2mM
L-glutamine mixture (Invitrogen). Additionally, the culture
media for the recombinant HeLa cells included one or more of
the following selection antibiotics: 100 g/ml hygromycin
(Invitrogen) (for Gal4-ELK1), 100 or 400 g/ml geneticin
(Invitrogen) (for GAL4-TATA-LUC), and 2 g/ml puromycin
(Sigma) (for AR or AR(A/B)-VP16). For hormone depletion,
LNCaP cells were grown in phenol red-free RPMI 1640
medium supplemented with 10% heat-inactivated and char-
coal-stripped FBS (Sigma) and 100 units/ml penicillin, 100
g/ml streptomycin, 2 mM L-glutamine mixture for 96 h before
each experiment. For hormone depletion, parental and recom-
binant HeLa cells were grown in phenol red-free DMEM sup-
plemented with 5% heat-inactivated and charcoal-stripped FBS
(Sigma) and 2mM L-glutamine for 48 h before each experiment.
Affinity-purified rabbit anti-human antibody to AR (sc-7305)
andmouse antibodies to Gal4 (sc-510) and GAPDH (sc-47724)
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Rabbit monoclonal anti-human antibody to ERK1/ERK2
(ab17942), rabbit monoclonal anti-human to androgen recep-
tor-ChIP grade antibody (ab74272), rabbit monoclonal anti-
human antibody to ELK1 (ab32106), and mouse monoclonal
anti-human antibodies to the androgen receptor (ab77557) and
ELK1 (ab7712)were fromAbcam (Cambridge,MA). R1881was
kindly provided by Dr. Steve Patrick (Wayne State University/
Karmanos Cancer Institute, Detroit, MI). Testosterone was
from Sigma. LipofectamineTM 2000 was purchased from
Thermo Scientific (product number 78410). Trametinib was
purchased from Selleckchem. AKTi-1/2 was purchased from
EMDMillipore (Darmstadt, Germany). The endoribonuclease-
prepared siRNAs were purchased from Sigma.
Purified Proteins—Full-length humanAR expressed in insect
cells and purified to 95% by affinity chromatography and
FPLC (ab82609) was purchased fromAbcam (CambridgeMA).
Recombinant His-tagged ELK1 as well as His-tagged ELK1
mutated in both the D-box(308–321) and the DEF motif
(F397L, P398A) expressed from baculovirus-infected Sf9 cells
were purified using nickel-agarose affinity chromatography.
The proteins were eluted with 200 mM imidazole and dialyzed
against 20 M HEPES, pH 7.9, containing 10% glycerol, 20 mM
KCl, 2 mMMgCl2, 0.2 mM EDTA, 0.5 mM benzamidine, and 0.5
mM DTT. Purity of the proteins was estimated to be 85% by
SDS-PAGE.
Surface Plasmon Resonance—Amine coupling kit, CM5 sen-
sor chip, and HBS-N buffer (GE Healthcare) were used for SPR
analysis. The rate and equilibrium binding constants of the
interaction of AR with ELK1 or mutant ELK1 were determined
using BIAcore 3000 (BIAcore, Piscataway, NJ). Affinity-puri-
fied AR polypeptide (ligand) was immobilized on a CM5
research grade sensor chip by an amine coupling method (60).
The immobilization involved activation of carboxymethyl
groups on a dextran-coated chip by reaction with N-hydroxy-
succinimide, followed by covalent bonding of the ligand to the
chip surface via amide linkages. Reference surfaces were pre-
pared in the same manner but blocked with ethanolamine and
thus contained no ligand. Kinetic binding analysis was carried
out by injecting affinity-purified ELK1 polypeptide at different
concentrations (0–160 nM) or mutant ELK1 (100 nM) into the
flow cells (ligand and reference cell), and the interaction
(response units (RU)) between analyte and ligand was recorded
as the ligand RU minus the reference RU. Kinetic values were
determined using BIAevaluation software (BIAcore), and the
data were fitted with the model showing the closest match (61,
62). A 1:1 Langmuir binding model was generally selected, in
which all the sensorgrams representing the different analyte
concentrations were fitted simultaneously with the wide win-
dow of association and dissociation phases. Individual concen-
tration curves were also evaluated to confirm the fitting data.
The equilibrium dissociation constant (Kd) was calculated by
Kd koff/kon.
Plasmids—The expression plasmid for human full-length
ELK1in the pCMV plasmid was purchased from OriGene
(Rockville, MD). The pLenti-GIII-CMV-hELK1 lentiviral vec-
tor was from Applied Biological Materials Inc. The GAL4-
TATA-LUC plasmid (pG5luc-Promega) and expression plas-
mid for VP16 and Gal4 were purchased from Promega
(Madison, WI) (CheckMate Mammalian Two-hybrid System).
The pRL plasmid encoding Renilla luciferase was purchased
from Promega. The PatheDetect pFC-MEK1 trans-reporter
plasmid with an S218E/S222E point mutation and internal
deletion between amino acid residues 32 and 51 rendering it
constitutively active was from Stratagene. The pLVX-AR-V7
plasmid and pLVX control plasmid were the kind gifts fromDr.
Yan Dong, Tulane University (New Orleans, LA). Details of all
other plasmid constructs generated in this work are provided in
the supplemental material.
siRNA-mediatedGeneKnockdown—The appropriate recom-
binant HeLa cells were plated in a 6-well plate (CytoOne, from
USA Scientific) in DMEM supplemented with 10% FBS and 2
mM L-glutamine 24 h before transfection. The following day,
cells were transfected with esiRNAs against ERK1 (MAPK3, 1
g) and ERK2 (MAPK1, 1 g) or 2 g of control siRNA using
LipofectamineTM 2000.
Co-immunoprecipitation—HeLa cells were transfected with
the expression plasmid for AR and co-transfected with expres-
sion plasmid for WTELK1 or ELK1308–321 or ELK1 FxLa.
Cells were harvested in radioimmunoprecipitation assay lysis
buffer and 1 protease inhibitor mixture 48 h post-transfec-
tion. Whole cell lysates (500 g) were pre-cleared for 2 h using
protein A-agarose beads (Calbiochem). Immunoprecipitation
was performed by first incubating 100 l of the protein A-aga-
rose beadswith 20g of the anti-rabbit androgen receptor anti-
body (ab74272) or negative control for 4 h. After washing the
antibody-bound beads three times, 500g of the cell lysate was
added and incubated at 4 °C overnight under rotary agitation.
At the end of the incubation, the complexes were washed five
times with the radioimmunoprecipitation assay buffer. The
Western blotting was probed with mouse monoclonal AR
antibody (ab77557) and mouse monoclonal ELK1 antibody
(ab7712).
Other Experimental Methods—Transient transfection and
luciferase reporter assays, Checkmate mammalian two-hybrid
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assay, lentivirus-mediated gene knockdown and gene expres-
sion, cell proliferation assay, Western blotting analysis, RNA
isolation, reverse transcription, and real time PCR have been
described in Ref. 31.
Statistical Analysis—All experiments were performed in
triplicate and repeated at least three times. The error bars in all
graphs represent the standard deviation. Statistical analysis was
performedusing one-way analysis of variancewith post hoc and
least square differences and/or t test. The p values are indicated
in the figure legends.
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